New LaunchJun 23, 2026, 08:06 AM
Alps Group Launches Patient-Derived Organoid Program via Partnership
AI Summary
Alps Group Inc announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Axiocell Biotech. The company is launching an internal PDO program focused on personalized cancer treatment and preclinical drug screening, aiming to develop Malaysia’s first clinically validated PDO platform. This move positions Alps in a rapidly growing market, with the global human organoids market projected to reach $349.5 million by 2036 and the personalized cancer treatment market $332.37 billion by 2030.
Key Highlights
- Alps Group Inc is expanding into patient-derived organoid (PDO) technology.
- Launching an internal PDO program for personalized cancer treatment and preclinical drug screening.
- Partnership with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech.
- Global human organoids market valued at $91.8M in 2026, projected to reach $349.5M by 2036.
- Global personalized cancer treatment market valued at $222.54B in 2026, projected to reach $332.37B by 2030.
- Aims to develop Malaysia’s first clinically validated PDO platform.
- Plans to establish a national PDO biobank to support preclinical drug screening.
Price Impact
More from ALPS